Combination Drug Approved for High Blood Pressure
Tribenzor sanctioned for those who don't respond to other drugs
Topics: Blood Pressure Drug Approvals Food & Drug Administration Heart / Stroke-Related: High Blood Pressure
MONDAY, July 26 (HealthDay News) -- Tribenzor, a three-in-one drug to treat high blood pressure, has been approved by the U.S. Food and Drug Administration.
Tribenzor combines amlodipine, marketed by Pfizer as Norvasc, olmesartan medoxomil, marketed by Daiichi Sankyo as Benicar, and a third drug, hydrochlorothiazide. The combination medication was approved for people whose high blood pressure isn't well controlled on other combinations of anti-hypertension drugs.
Daiichi Sankyo, based in Japan with U.S. headquarters in Parsippany, N.J., produces the newly approved drug.
In a news release, the company said adverse reactions to once-daily Tribenzor could include dizziness, swelling, headache, fatigue, muscle spasms, nausea, diarrhea or infections of the respiratory or urinary tracts.
More information
To learn more about high blood pressure, visit the U.S. National Heart Lung and Blood Institute.
Categories
Choose one of our special categories to view or subscribe
- Aging
- Allergies
- Arthritis
- Asthma
- Bone Health
- Cancer
- Cardiovascular Health
- Children's Health
- Colds, Flu, and Infectious Diseases
- Dental Health
- Diabetes
- Diet and Healthy Eating
- Digestive Health
- Drugs and Supplements
- Emotional and Mental Health
- Fitness and Exercise
- Geriatric Care
- Incontinence
- Men's Health
- Menopause
- Neurologic Health
- Pregnancy
- Sexual Health
- Skin Problems
- Sleep Disorders
- Stroke
- Vaccinations
- Weight Management
- Women's Health
